Cellanome

Executive Summary

Cellanome is a San Diego-based private biotechnology company developing a novel live-cell multimodal platform that integrates molecular, functional, and temporal data from individual cells over time. Its proprietary CellCage™ technology enables dynamic, AI-ready insights, positioning the company to advance single-cell and multiomic discovery. By linking diverse data types from the same cells, the platform has the potential to uncover new biological mechanisms and accelerate drug development, particularly in oncology, immunology, and neuroscience. Although the company is early-stage with no disclosed funding or commercial products, its innovative approach addresses a critical gap in single-cell analysis, which typically lacks temporal and functional context. If successfully commercialized, Cellanome could become a key tool for researchers seeking comprehensive, real-time cellular profiles. The platform's reliance on AI-ready data also aligns with broader trends in AI-driven drug discovery, though the path to market and competitive differentiation remain to be validated. Given the early stage, conviction is moderate pending further milestones.

Upcoming Catalysts (preview)

• Q3 2026Series A or Seed Funding Announcement60% success
• Q4 2026Partnership or Collaboration with Major Pharma30% success
• Q2 2026Publication of Proof-of-Concept Data in Peer-Reviewed Journal70% success